drugset

drugset / Trial / NCT00632736

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

NCT00632736 ↗

Phase 3 Completed 419 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease

Timeline

Start: 2004-02
Primary completion: 2010-03
Completion: 2010-03

Publications

Makumi CW, Asgharian A, Ellis J, Shaikh S, Jimenez T, VanMeter S. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease. Int J Neurosci. 2016;126(1):30-8. doi: 10.3109/00207454.2014.991924. Epub 2014 Dec 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ropinirole	Small molecule	24 mg	—

Indications